Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: Potential antioxidant effects (Am J Physiol Heart Circ Physiol, (2013), 304, H538-H546, 10.1177/0956797615572905);Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: Potential antioxidant effects

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 4, 2013, Pages H1861-

  Dokken, Betsy B ^a,b,c   Piermarini, Charles V ^a,c   Teachey, Mary K ^a   Gura, Michael T ^b,c   Dameff, Christian J ^b,c   Heller, Brian D ^b,c   Krate, Jonida ^a   Ashgar, Aeen M ^a   Querin, Lauren ^a,c   Mitchell, Jennifer L ^a   Hilwig, Ronald W ^b,c   Kern, Karl B ^a,b,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Coronary flow reserve; Endothelium; Incretin; Microcirculation; Swine

Indexed keywords

8 ISO PROSTAGLANDIN F2 ALPHA; CYCLOOXYGENASE 2; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PLACEBO; PROSTAGLANDIN F2 ALPHA; RECOMBINANT PROTEIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY BLOOD VESSEL; CORONARY FLOW RESERVE; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART ARREST; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE RELAXATION; HEART VENTRICLE FIBRILLATION; INSULIN BLOOD LEVEL; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESUSCITATION; RETURN OF SPONTANEOUS CIRCULATION; SURVIVAL; SWINE; VASCULAR ENDOTHELIUM;

EID: 84874053312     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.zh4-0651-corr.2018     Document Type: Erratum

References (108)

1. Adrie C, Laurent I, Monchi M, Cariou A, Dhainaou JFo, Spaulding C. Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? Current Opinion in Critical Care 10: 208-212, 2004.
2. Araszkiewicz A, Lesiak M, Grajek S, Prech M, Grygier M, Mularek-Kubzdela T, Cieslinski A. Effect of microvascular reperfusion on prognosis and left ventricular function in anterior wall myocardial infarction treated with primary angioplasty. International Journal of Cardiology 114: 183-187, 2007.
3. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and-independent pathways. Circulation 117: 2340-2350, 2008.
4. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 293: E1289-E1295, 2007.
5. Basu S, Miclescu A, Sharma H, Wiklund L. Propofol mitigates systemic oxidative injury during experimental cardiopulmonary cerebral resuscitation. Prostaglandins, Leukotrienes and Essential Fatty Acids 84: 123-130, 2011.
6. Basu S, Nozari A, Liu XL, Rubertsson S, Wiklund L. Development of a novel biomarker of free radical damage in reperfusion injury after cardiac arrest. FEBS Lett 470: 1-6, 2000.
7. Behringer W, Safar P, Kentner R, Wu X, Kagan VE, Radovsky A, Clark RSB, Kochanek PM, Subramanian M, Tyurin VA, Tyurina YY, Tisherman SA. Antioxidant tempol enhances hypothermic cerebral preservation during prolonged cardiac arrest in dogs. J Cereb Blood Flow Metab 22: 105-117, 2002.
8. Bertuglia S, Giusti A. Microvascular oxygenation, oxidative stress, NO suppression and superoxide dismutase during postischemic reperfusion. Am J Physiol Heart Circ Physiol 285: H1064-H1071, 2003.
9. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, Hussein MA. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34: 90-95, 2011.
10. Biaggioni I. Clinical and molecular pharmacologic characteristics of adenosine-induced vasodilation. Clin Pharmacol Ther 75: 137-139, 2004.
11. Bloomgarden ZT. Incretin concepts. Diabetes Care 33: e20-e25, 2010.
12. Bolognese L, Carrabba N, Parodi G, Santoro GM, Buonamici P, Cerisano G, Antoniucci D. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 109: 1121-1126, 2004.
13. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagonlike peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151, 2005.
14. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Myocardial infarct size attenuation by glucagon like peptide-1 (GLP-1) in both in vivo and in vitro rat heart. In: Diabetologia. Germany: Springer, 2004, p. 117.
15. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemiareperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovascular Drugs and Therapy 21: 253-256, 2007.
16. Brown SB, Libonati JR, Selak MA, Shannon RP, Simmons RA. Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart. Cardiovascular Drugs and Therapy 24: 197-205, 2010.
17. Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145: 2653-2659, 2004.
18. Cabou C, Campistron Gr Marsollier N, Leloup C, Cruciani-Guglielmacci C, Panicaud L, Drucker DJ, Magnan C, Burcelin Rm. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 57: 2577-2587, 2008.
19. Carnevale R, Loffredo L, Pignatelli P, Nocella C, Bartimoccia S, Di Santo S, Martino F, Catasca E, Perri L, Violi F. Dark chocolate inhibits platelet isoprostanes via NOX2 down-regulation in smokers. J Thromb Haemost 10: 125-132, 2012.
20. Ceriello A, Esposito K, Testa R, Bonfigli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide-1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagonlike peptide-1 in diabetes. Diabetes Care 34: 697-702, 2011.
21. Chaudhuri A, Ghanim H, Vora M, Ling Sia C, Korzeniewski K, Dhindsa S, Makdissi A, Dandona P. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 97: 198-207, 2012.
22. Chen J, Couto FM, Minn AH, Shalev A. Exenatide inhibits [beta]-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 346: 1067-1074, 2006.
23. Cracowski JL, Devillier P, Durand T, Stanke-Labesque F, Bessard G. Vascular biology of the isoprostanes. J Vasc Res 38: 93-103, 2001.
24. Dan Y, Shubin G, Tianpeng Z, Huihua L. Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling. FEBS Lett 583: 2500-2506, 2009.
25. Daray FM, Minvielle AI, Puppo S, Rothlin RP. Vasoconstrictor effects of 8-iso-prostaglandin E2 and 8-iso-prostaglandin F2a on human umbilical vein. Eur J Pharmacol 499: 189-195, 2004.
26. Delanty N, Reilly MP, Pratico D, Lawson JA, McCarthy JF, Wood AE, Ohnishi ST, Fitzgerald DJ, FitzGerald GA. 8-Epi PGF2a generation during coronary reperfusion: a potential quantitative marker of oxidant stress in vivo. Circulation 95: 2492-2499, 1997.
27. Dokken BB, Hilwig WR, Teachey MK, Panchal RA, Huebner K, Allen D, Rogers DC, Kern KB. Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction. Resuscitation 81: 755-760, 2010.
28. Dokken BB, La Bonte LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res 43: 300-305, 2011.
29. Dokken BB, Labonte LR, Davis-Gorman G, McDonagh PF. Postconditioning with GLP-1 in vivo decreases myocardial infarct size in rats. Diabetes 56: A15-A16, 2007.
30. Donadello K, Favory R, Salgado-Ribeiro D, Vincent JL, Gottin L, Scolletta S, Creteur J, De Backer D, Taccone FS. Sublingual and muscular microcirculatory alterations after cardiac arrest: a pilot study. Resuscitation 82: 690-695, 2011.
31. Dozier KC, Cureton EL, Kwan RO, Curran B, Sadjadi J, Victorino GP. Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 30: 1735-1741, 2009.
32. Edwards G, Félétou M, Gardener MJ, Glen CD, Richards GR, Vanhoutte PM, Weston AH. Further investigations into the endothelium-dependent hyperpolarizing effects of bradykinin and substance P in porcine coronary artery. Br J Pharmacol 133: 1145-1153, 2001.
33. Emamaullee JA, Merani S, Toso C, Kin T, Al-Saif F, Truong W, Pawlick R, Davis J, Edgar R, Lock J, Bonner-Weir S, Knudsen LB, Shapiro AMJ. Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology 150: 2145-2152, 2009.
34. Fries M, Ristagno G. Cool flow-The microcirculation in cardiac arrest patients treated with therapeutic hypothermia. Resuscitation 82: 651-652, 2011.
35. Fries M, Tang WC, Chang YT, Wang JL, Castillo C, Weil MH. Microvascular blood flow during cardiopulmonary resuscitation is predictive of outcome. Resuscitation 71: 248-253, 2006.
36. Fries M, Weil MH, Chang YT, Castillo C, Tang WC. Microcirculation during cardiac arrest and resuscitation. Critical Care Medicine 34: S454-S457, 2006.
37. Gardan B, Cracowski JL, Sessa C, Hunt M, Stanke-Labesque F, Devillier P, Bessard G. Vasoconstrictor effects of iso-prostaglandin F2a type-III (8-iso-prostaglandin F2a) on human saphenous veins. J Cardiol 35: 729-734, 2000.
38. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circulation Research 87: 26-32, 2000.
39. Grieb P, Ryba MS, Debicki GS, Gordon-Krajcer W, Januszewski S, Chrapusta SJ. Changes in oxidative stress in the rat brain during post-cardiac arrest reperfusion, and the effect of treatment with the free radical scavenger idebenone. Resuscitation 39: 107-113, 1998.
40. Grieb P, Ryba MS, Debicki GS, Gordon-Krajcer W, Januszewski S, Chrapusta SJ. Changes in oxidative stress in the rat brain during post-cardiac arrest reperfusion, and the effect of treatment with the free radical scavenger idebenone. Resuscitation 39: 107-113, 1998.
41. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H Oxidase: role in cardiovascular biology and disease. Circulation Research 86: 494-501, 2000.
42. Gross DR, Fiscus RR, Arden WA, Maley RH, Lanzo S, Salley RK. Substance P induces biphasic endothelium-dependent relaxations in pig and rabbit carotid arteries. Neuropeptides 26: 329-341, 1994.
43. Gutierrez G. F2-isoprostanes: potential markers of oxidative stress during resuscitation. Critical Care Medicine 33: 2137-2138, 2005.
44. Henriques JPS, Zijlstra F, Ottervanger JP, de Boer MJ, van =t Hof AWJ, Hoorntje JCA, Suryapranata H. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 23: 1112-1117, 2002.
45. Hiss FC, Lascala TF, Maciel BC, Marin-Neto JA, Simoes MV. Changes in myocardial perfusion correlate with deterioration of left ventricular systolic function in chronic Chagas= cardiomyopathy. J Am Coll Cardiol 2: 164-172, 2009.
46. Hoffmann R, Haager P, Arning J, Christott P, Radke P, Blindt Rd Ortlepp J, Lepper W, Hanrath P. Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function. Am J Cardiol 92: 1015-1019, 2003.
47. Hombach V, Grebe O, Merkle N, Waldenmaier S, Höher M, Kochs M, Wöhrle J, Kestler HA. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 26: 549-557, 2005.
48. Hou X, Gobeil F, Peri K, Speranza G, Marrache AM, Lachapelle P, Roberts J, Varma DR, Chemtob S, Ellis EF. Augmented vasoconstriction and thromboxane formation by 15-F2a-isoprostane (8-iso-prostaglandin F2a) in immature pig periventricular brain microvessels. Stroke 31: 516-524, 2000.
49. Huisamen B, Genade S, Lochner A. Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. Cardiovascular Journal of Africa 19: 77-83, 2008.
50. Idris AH, Roberts LJI, Caruso L, Showstark M, Layon AJ, Becker LB, Hoek TV, Gabrielli A. Oxidant injury occurs rapidly after cardiac arrest, cardiopulmonary resuscitation, and reperfusion. Critical Care Medicine 33: 2043-2048, 2005.
51. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 391: 1405-1408, 2010.
52. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T. Clinical implications of the =no reflow= phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 93: 223-228, 1996.
53. Jimenez-Feltstrom J, Lundquist I, Salehi A. Glucose stimulates the expression and activities of nitric oxide synthases in incubated rat islets: an effect counteracted by GLP-1 through the cyclic AMP/PKA pathway. Cell and Tissue Research 319: 221-230, 2005.
54. Kern K, Hilwig R, Rhee K, Berg R. Myocardial dysfunction after resuscitation from cardiac arrest: an example of global myocardial stunning. J Am Coll Cardiol 28: 232-240, 1996.
55. Kern KB, Berg RA, Hilwig RW, Larson DF, Gaballa MA. Myocardial cytokine IL-8 and nitric oxide synthase activity during and after resuscitation: preliminary observations in regards to post-resuscitation myocardial dysfunction. Resuscitation 77: 401-409, 2008.
56. Kern KB, Sasaoka T, Higashi H, Hilwig RW, Berg RA, Zuercher M. Post-resuscitation myocardial microcirculatory dysfunction is ameliorated with eptifibatide. Resuscitation 82: 85-89, 2011.
57. Kern KB, Zuercher M, Cragun D, Ly S, Quash J, Bhartia S, Hilwig RW, Berg RA, Ewy GA. Myocardial microcirculatory dysfunction after prolonged ventricular fibrillation and resuscitation. Critical Care Medicine 36: S418-S421, 2008.
58. Klein T, Reutter F, Schweer H, Seyberth HW, Nusing RM. Generation of the isoprostane 8-epi-prostaglandin F2a in vitro and in vivo via the cyclooxygenases. Journal of Pharmacology and Experimental Therapeutics 282: 1658-1665, 1997.
59. Krier JD, Rodriguez-Porcel M, Best PJM, Romero JC, Lerman A, Lerman LO. Vascular responses in vivo to 8-epiPGF2a in normal and hypercholesterolemic pigs. Am J Physiol Regul Integr Comp Physiol 283: R303-R308, 2002.
60. Ladwig KH, Sshoefinius A, Danner R, Gurtler R, Herman R, Koeppel A, Hauber P. Effects of early defibrillation by ambulance personnel on short-and long-term outcome of cardiac arrest survival-The Munich experiment. Chest 112: 1584-1591, 1997.
61. Lavi S, Yang EH, Prasad A, Mathew V, Barsness GW, Rihal CS, Lerman LO, Lerman A. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension 51: 127-133, 2008.
62. Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 274: 24441-24444, 1999.
63. Liu Fq Zhang Xl Gong L, Wang Xp Wang J, Hou Xg Sun Y, Qin Wd Wei Sj Zhang Y, Chen L, Zhang MX. Glucagon-like peptide 1 protects microvascular endothelial cells by inactivating the PARP-1/iNOS/NO pathway. Molecular and Cellular Endocrinology 339: 25-33, 2010.
64. Liu H, Dear A, Knudsen L, Simpson R. A long-acting GLP-1 analogue attenuates induction of PAI-1 and vascular adhesion molecules. J Endocrinol 201: 59-66, 2009.
65. Liu H, Hu Y, Simpson RW, Dear AE. Glucagon-like peptide-1 attenuates tumour necrosis factor-(alpha)-mediated induction of plasminogen activator inhibitor-1 expression. J Endocrinol 196: 57-65, 2008.
66. Loukogeorgakis SP, van den Berg MJ, Sofat R, Nitsch D, Charakida M, Haiyee BH, de Groot E, MacAllister RJ, Kuijpers TW, Deanfield JE. Role of NADPH oxidase in endothelial ischemia/reperfusion injury in humans. Circulation 121: 2310-2316, 2010.
67. Mehlhorn U, Krahwinkel A, Geissler HJ, LaRosee K, Fischer UM, Klass O, Suedkamp M, Hekmat K, Tossios P, Bloch W. Nitrotyrosine and 8-isoprostane formation indicate free radical-mediated injury in hearts of patients subjected to cardioplegia. J Thorac Cardiovasc Surg 125: 178-183, 2003.
68. Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: markers and mediators of oxidative stress. FASEB J 18: 1791-1800, 2004.
69. Morrow JD, Roberts LJ. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med 166: S25-S30, 2002.
70. Muangman P, Muffley L, Gibran N. Substance P induces nitric oxide production in human microvascular endothelial cells. Wound Repair Regen 13: A28-A48, 2005.
71. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. Circulation 125: 1043-1052, 2012.
72. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academies Press, 2010.
73. Neglia D, Michelassi C, Trivieri MG, Sambuceti G, Giorgetti A, Pratali L, Gallopin M, Salvadori P, Sorace O, Carpeggiani C, Poddighe R, Lâbbate A, Parodi O. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular sysfunction. Circulation 105: 186-193, 2002.
74. Nikolaidis L, Doverspike A, Hentosz T, Zourelias L, Shen Y, Elahi D, Shannon R. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 312: 303-308, 2005.
75. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen Yt, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110: 955-961, 2004.
76. Nolan JP, Neumar RW, Adrie C, Aibiki M, Berg RA, Böttiger BW, Callaway C, Clark RSB, Geocadin RG, Jauch EC, Kern KB, Laurent I, Longstreth WT, Merchant RM, Morley P, Morrison LJ, Nadkarni V, Peberdy MA, Rivers EP, Rodriguez-Nunez A, Sellke FW, Spaulding C, Sunde K, Hoek TV. Post-cardiac arrest syndrome: Epidemiology, pathophysiology, treatment, and prognostication: a scientific statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke. Resuscitation 79: 350-379, 2008.
77. Nystrom T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res 40: 593-606, 2008.
78. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209-E1215, 2004.
79. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Sillje HHW. Glucagon-like peptide-1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 30: 1407-1414, 2010.
80. Pignatelli P, Carnevale R, Di Santo S, Bartimoccia S, Sanguigni V, Lenti L, Finocchi A, Mendolicchio L, Soresina AR, Plebani A, Violi F. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol 31: 423-434, 2011.
81. Poornima I, Brown S, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 (GLP-1) infusion sustains LV systolic function and prolongs survival in the spontaneously hypertensive-heart failure prone rat. Circ Heart Fail 1: 153-160, 2008.
82. Potenza MA, Gagliardi S, De Benedictis L, Zigrino A, Tiravanti E, Colantuono G, Federici A, Lorusso L, Benagiano V, Quon MJ, Montagnani M. Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am J Physiol Endocrinol Metab 297: E685-E694, 2009.
83. Puddu A, Storace D, Durante A, Odetti P, Viviani GL. Glucagon-like peptide-1 counteracts the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T 15. Biochem Biophys Res Commun 398: 462-466, 2010.
84. Ragosta M, Camarano G, Kaul S, Powers E, Sarembock I, Gimple L. Microvascular integrity indicates myocellular viability in patients with recent myocardial infarction. New insights using myocardial contrast echocardiography. Circulation 89: 2562-2569, 1994.
85. Ramaraj R, Movahed M. Microvascular dysfunction following primary percutaneous coronary intervention in the setting of ST-elevation myocardial infarction. Journal of Invasive Cardiology 20: 603-614, 2008.
86. Ravassa S, Zudaire A, Carr RD, Diez J. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol 300: H1361-H1372, 2011.
87. Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NEJ, Dutka DP. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circulation: Cardiovascular Interventions 4: 266-272, 2011.
88. Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 98: 408-413, 2012.
89. Reilly MP, Delanty N, Roy L, Rokach J, Callaghan PO, Crean P, Lawson JA, FitzGerald GA. Increased formation of the isoprostanes IPF2a and 8-epi-prostaglandin F2a in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation 96: 3314-3320, 1997.
90. Rigo F, Gherardi S, Galderisi M, Pratali L, Cortigiani L, Sicari R, Picano E. The prognostic impact of coronary flow-reserve assessed by Doppler echocardiography in non-ischaemic dilated cardiomyopathy. Eur Heart J 27: 1319-1323, 2006.
91. Ruef J, Moser M, Bode C, Kübler W, Runge MS. 4-Hydroxynonenal induces apoptosis, NF-B-activation and formation of 8-isoprostane in vascular smooth muscle cells. Basic Res Cardiol 96: 143-150, 2001.
92. Sakamoto H, Corcoran TB, Laffey JG, Shorten GD. Isoprostanes-markers of ischaemia reperfusion injury. Eur J Anaesthesiol 19: 550-559, 2002.
93. Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Critical Care Medicine 32: 1825-1831, 2004.
94. Sakuma T, Hayashi Y, Sumii K, Imazu M, Yamakido M. Prediction of short-and intermediate-term prognoses of patients with acute myocardial infarction using myocardial contrast echocardiography one day after recanalization. J Am Coll Cardiol 32: 890-897, 1998.
95. Schoenenberger RA, Vonplanta M, Vonplanta I. Survival after failed out-of-hospital resuscitation-are further therapeuitc efforts in the emergency department futile? Arch Intern Med 154: 2433-2437, 1994.
96. Sharma AB, Knott EM, Bi J, Martinez RR, Sun J, Mallet RT. Pyruvate improves cardiac electromechanical and metabolic recovery from cardiopulmonary arrest and resuscitation. Resuscitation 66: 71-81, 2005.
97. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12: 694-699, 2006.
98. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146: 243-249, 2008.
99. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 39: 591-597, 2002.
100. Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H, Hattori N, Urabe T. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 31: 1696-1705, 2011.
101. Timmers L, Henriques JPS, de Kleijn DPV, DeVries JH, Kemperman H, Steendijk P, Verlaan CWJ, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury. J Am Coll Cardiol 53: 501-510, 2009.
102. Ting H, Khasawneh F. Platelet function and isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family? Journal of Biomedical Science 17: 24, 2010.
103. Tomas E, Stanojevic V, Habener JF. GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 167: 177-184, 2011.
104. Urusova IA, Farilla L, Hui H, Amico E, Perfetti R. GLP-1 inhibition of pancreatic islet cell apoptosis. Trends Endocrinol Metab 15: 27-33, 2003.
105. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JAC. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 97: 765-772, 1998.
106. Yin H, Havrilla CM, Gao L, Morrow JD, Porter NA. Mechanisms for the formation of isoprostane endoperoxides from arachidonic acid. J Biol Chem 278: 16720-16725, 2003.
107. Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A. Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int 56: 471-478, 1999.
108. Zhao TC, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. Journal of Pharmacology and Experimental Therapeutics 317: 1106-1113, 2006.